STAT Plus: ViiV takes steps to widen access to HIV prevention drug, but continues to encounter criticism
Pharmalot
Ed Silverman began writing Pharmalot at The Star Ledger of New Jersey in 2007 and it continues to this day at STAT. He joined STAT at its founding in 2015, coming from the Wall Street Journal. He has covered the pharmaceutical industry since 1995.
Latest
STAT Plus: U.S. Supreme Court asks solicitor general for views on controversial Oklahoma law for regulating PBMs
STAT Plus: Pharmalittle: We’re reading about compounders suing the FDA, Biogen turning to telehealth, and more
STAT Plus: Compounding group sues FDA for removing Lilly’s obesity drug from its shortages list
STAT Plus: Pharmalittle: We’re reading about an activist investor stake in Pfizer, Trump backing off drug-pricing plan, and more
STAT Plus: Up and down the ladder: The latest comings and goings
STAT Plus: Pharmalittle: We’re reading about an Italian acquisition, Medicare Advantage market growth, and more
STAT Plus: Pharmalittle: We’re reading about Chinese drugmakers weighing sales, Medicare price talks, and more
All Coverage
advertisement
